Kim Ann Mink
Kim Ann Mink's purchase track record
Kim Ann Mink has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2025 | EMN | $101K | -9.9% | +12.5% | +7.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Eastman Chemical faces lower price targets from UBS, Mizuho, Citi. Three major banks recently lowered their price targets for Eastman Chemical, citing ongoing industry pressures. Despite these reductions, all firms maintained positive ratings on the stock. The company continues to offer a dividend yield of 3.86%, which remains a key feature for income-focused investors.
Transaction History
| AVNT | ▲ Buy | Grant | 958 | $0 | 9/30/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,049 | $0 | 6/30/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,072 | $0 | 3/31/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,239 | $0 | 12/31/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,192 | $0 | 9/30/2025 | View on chart |
| EMN | ▲ Buy | Open Market | 1,450 | $101K | 8/27/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,187 | $0 | 6/30/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,055 | $0 | 3/31/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 955 | $0 | 12/31/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 775 | $0 | 9/30/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 806 | $0 | 6/28/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 808 | $0 | 3/29/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 834 | $0 | 12/29/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 984 | $0 | 9/29/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 863 | $0 | 6/30/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 857 | $0 | 3/31/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 1,040 | $0 | 12/31/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 1,139 | $0 | 9/30/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 880 | $0 | 6/30/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 717 | $0 | 3/31/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 627 | $0 | 12/31/2021 | View on chart |
| AVNT | ▲ Buy | Grant | 744 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avient Announces New CEO Mike Frank, Reaffirms Guidance
Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.
Avient Announces New CEO Mike Frank, Reaffirms Guidance. Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.